Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state

Sara Lawrence-Mills; Melanie J Hezzell; Sophie E Adamantos; Iris Chan; Kieran Borgeat; Jessie Rose Payne; Simon C Satchell; Gavin I Welsh; R R Foster; Natalie C Finch

doi:10.1016/j.tvjl.2022.105845

Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state

Sara Lawrence-Mills^*, Melanie J Hezzell, Sophie E Adamantos, Iris Chan, Kieran Borgeat, Jessie Rose Payne, Simon C Satchell, Gavin I Welsh, R R Foster, Natalie C Finch

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

4 Citations (Scopus)

71 Downloads (Pure)

Abstract

The endothelial glycocalyx (eGlx) lines the luminal surface of endothelial cells, maintaining vascular health. Glycocalyx damage is pathophysiologically important in many diseases across species however few studies have investigated its breakdown in naturally occurring disease in dogs. The aims of the study were to investigate eGlx damage in dogs with myxomatous mitral valve disease (MMVD) diagnosed on echocardiography, and dogs in a hypercoagulable state diagnosed using thromboelastography (TEG), by measuring serum hyaluronan concentrations. Serum hyaluronan was quantified in dogs with MMVD (n = 27), hypercoagulability (n = 21), and in healthy controls dogs (n = 18). Serum hyaluronan concentrations were measured using a commercially-available ELISA validated for use in dogs. Hyaluronan concentrations were compared among groups using Kruskal-Wallis tests, and post-hoc with Dunn’s tests. Serum hyaluronan concentrations (median [range]) were significantly increased in dogs with MMVD (62.4 [22.8–201] ng/mL; P = 0.031) and hypercoagulability (92.40 [16.9–247.6] ng/mL; P < 0.001) compared to controls (45.7 [8.7–80.2] ng/mL). Measurement of serum hyaluronan concentration offers a clinically applicable marker of eGlx health and suggests the presence of eGlx damage in dogs with MMVD and dogs in a hypercoagulable state.

Original language	English
Article number	105845
Number of pages	4
Journal	Veterinary Journal
Volume	285
Early online date	28 May 2022
DOIs	https://doi.org/10.1016/j.tvjl.2022.105845
Publication status	Published - 31 May 2022

Bibliographical note

Funding Information:
Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). In addition, Natalie Finch was funded by Wellcome Trust (104507/Z/14/Z).

Funding Information:
Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund ( 204813/Z/16/Z ). In addition, Natalie Finch was funded by Wellcome Trust ( 104507/Z/14/Z ).

Publisher Copyright:
© 2022 The Authors

Access to Document

10.1016/j.tvjl.2022.105845Licence: CC BY

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.tvjl.2022.105845 Please refer to any applicable terms of use of the publisher.
Final published version, 570 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Lawrence-Mills, S., Hezzell, M. J., Adamantos, S. E., Chan, I., Borgeat, K., Payne, J. R., Satchell, S. C., Welsh, G. I., Foster, R. R., & Finch, N. C. (2022). Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state. Veterinary Journal, 285, Article 105845. https://doi.org/10.1016/j.tvjl.2022.105845

@article{bb7705a5b7f24054beeb97a16f6613f6,

title = "Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state",

abstract = "The endothelial glycocalyx (eGlx) lines the luminal surface of endothelial cells, maintaining vascular health. Glycocalyx damage is pathophysiologically important in many diseases across species however few studies have investigated its breakdown in naturally occurring disease in dogs. The aims of the study were to investigate eGlx damage in dogs with myxomatous mitral valve disease (MMVD) diagnosed on echocardiography, and dogs in a hypercoagulable state diagnosed using thromboelastography (TEG), by measuring serum hyaluronan concentrations. Serum hyaluronan was quantified in dogs with MMVD (n = 27), hypercoagulability (n = 21), and in healthy controls dogs (n = 18). Serum hyaluronan concentrations were measured using a commercially-available ELISA validated for use in dogs. Hyaluronan concentrations were compared among groups using Kruskal-Wallis tests, and post-hoc with Dunn{\textquoteright}s tests. Serum hyaluronan concentrations (median [range]) were significantly increased in dogs with MMVD (62.4 [22.8–201] ng/mL; P = 0.031) and hypercoagulability (92.40 [16.9–247.6] ng/mL; P < 0.001) compared to controls (45.7 [8.7–80.2] ng/mL). Measurement of serum hyaluronan concentration offers a clinically applicable marker of eGlx health and suggests the presence of eGlx damage in dogs with MMVD and dogs in a hypercoagulable state.",

author = "Sara Lawrence-Mills and Hezzell, {Melanie J} and Adamantos, {Sophie E} and Iris Chan and Kieran Borgeat and Payne, {Jessie Rose} and Satchell, {Simon C} and Welsh, {Gavin I} and Foster, {R R} and Finch, {Natalie C}",

note = "Funding Information: Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). In addition, Natalie Finch was funded by Wellcome Trust (104507/Z/14/Z). Funding Information: Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund ( 204813/Z/16/Z ). In addition, Natalie Finch was funded by Wellcome Trust ( 104507/Z/14/Z ). Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = may,

day = "31",

doi = "10.1016/j.tvjl.2022.105845",

language = "English",

volume = "285",

journal = "Veterinary Journal",

issn = "1090-0233",

publisher = "Elsevier",

}

TY - JOUR

T1 - Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state

AU - Lawrence-Mills, Sara

AU - Hezzell, Melanie J

AU - Adamantos, Sophie E

AU - Chan, Iris

AU - Borgeat, Kieran

AU - Payne, Jessie Rose

AU - Satchell, Simon C

AU - Welsh, Gavin I

AU - Foster, R R

AU - Finch, Natalie C

N1 - Funding Information: Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). In addition, Natalie Finch was funded by Wellcome Trust (104507/Z/14/Z). Funding Information: Preliminary results were presented as an Abstract at the British Small Animal Veterinary Association Congress 2018 and the Southern European Veterinary Association Congress 2018. Support for travel to present the findings of the present study at scientific conferences was provided by MSD Animal Health. The Pet Blood Bank generously donated surplus blood samples from healthy donors. The authors would also like to thank all the staff at Langford Vets for their assistance with sample collection and storage. This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund ( 204813/Z/16/Z ). In addition, Natalie Finch was funded by Wellcome Trust ( 104507/Z/14/Z ). Publisher Copyright: © 2022 The Authors

PY - 2022/5/31

Y1 - 2022/5/31

N2 - The endothelial glycocalyx (eGlx) lines the luminal surface of endothelial cells, maintaining vascular health. Glycocalyx damage is pathophysiologically important in many diseases across species however few studies have investigated its breakdown in naturally occurring disease in dogs. The aims of the study were to investigate eGlx damage in dogs with myxomatous mitral valve disease (MMVD) diagnosed on echocardiography, and dogs in a hypercoagulable state diagnosed using thromboelastography (TEG), by measuring serum hyaluronan concentrations. Serum hyaluronan was quantified in dogs with MMVD (n = 27), hypercoagulability (n = 21), and in healthy controls dogs (n = 18). Serum hyaluronan concentrations were measured using a commercially-available ELISA validated for use in dogs. Hyaluronan concentrations were compared among groups using Kruskal-Wallis tests, and post-hoc with Dunn’s tests. Serum hyaluronan concentrations (median [range]) were significantly increased in dogs with MMVD (62.4 [22.8–201] ng/mL; P = 0.031) and hypercoagulability (92.40 [16.9–247.6] ng/mL; P < 0.001) compared to controls (45.7 [8.7–80.2] ng/mL). Measurement of serum hyaluronan concentration offers a clinically applicable marker of eGlx health and suggests the presence of eGlx damage in dogs with MMVD and dogs in a hypercoagulable state.

AB - The endothelial glycocalyx (eGlx) lines the luminal surface of endothelial cells, maintaining vascular health. Glycocalyx damage is pathophysiologically important in many diseases across species however few studies have investigated its breakdown in naturally occurring disease in dogs. The aims of the study were to investigate eGlx damage in dogs with myxomatous mitral valve disease (MMVD) diagnosed on echocardiography, and dogs in a hypercoagulable state diagnosed using thromboelastography (TEG), by measuring serum hyaluronan concentrations. Serum hyaluronan was quantified in dogs with MMVD (n = 27), hypercoagulability (n = 21), and in healthy controls dogs (n = 18). Serum hyaluronan concentrations were measured using a commercially-available ELISA validated for use in dogs. Hyaluronan concentrations were compared among groups using Kruskal-Wallis tests, and post-hoc with Dunn’s tests. Serum hyaluronan concentrations (median [range]) were significantly increased in dogs with MMVD (62.4 [22.8–201] ng/mL; P = 0.031) and hypercoagulability (92.40 [16.9–247.6] ng/mL; P < 0.001) compared to controls (45.7 [8.7–80.2] ng/mL). Measurement of serum hyaluronan concentration offers a clinically applicable marker of eGlx health and suggests the presence of eGlx damage in dogs with MMVD and dogs in a hypercoagulable state.

U2 - 10.1016/j.tvjl.2022.105845

DO - 10.1016/j.tvjl.2022.105845

M3 - Article (Academic Journal)

C2 - 35640794

SN - 1090-0233

VL - 285

JO - Veterinary Journal

JF - Veterinary Journal

M1 - 105845

ER -

Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state

Abstract

Bibliographical note

Access to Document

Handle.net

Fingerprint

Cite this